Timothy Compton is an accomplished professional who possesses extensive experience in commercial operations, including sales team management, business development, marketing and corporate development. As chief commercial officer, he is responsible for driving the continued growth of Avid’s CDMO business, including the ongoing expansion of the company’s commercial and clinical client base.
Prior to joining Avid in January of 2020, Mr. Compton served as senior director of sales and business development for Cambrex Corporation, a leading small molecule CDMO, where he managed the company’s Western North America and Asia Pacific CDMO sales and business development team. Following Cambrex’s 2019 acquisition of Avista Pharma Solutions, he played a key role in transitioning Avista’s commercial operations practices to Cambrex. Prior to its sale to Cambrex, Mr. Compton was vice president of sales for Avista, overseeing sales, business development and business operations across all the company’s service offerings, driving significant year-over-year revenue growth. Mr. Compton held multiple senior level positions with AAIPharma Services Corporation, a CDMO now named Alcami, including executive director of alliance management and executive director of business development. The last 23 years have also included tenures with a range of life science companies including Baypoint Biosystems, N.V. Organon, Kadmus Pharmaceuticals and Atairgin Technologies.
Timothy holds a B.S. in Microbiology from Washington State University and is an active duty veteran of the U.S. Army.